J.‐F. Yale

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

J.‐F. Yale, George L. Bakris, Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2013 · 480 citations · Full text

1998 clinical practice guidelines for the management of diabetes in Canada

S. J. Meltzer, Lawrence A. Leiter, Denis Daneman et al. · Canadian Medical Association Journal · 1998 · 379 citations

Obesity, Family Medicine, Metabolic Syndrome +15

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

J.‐F. Yale, G. Bakris, Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2014 · 270 citations

A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose‐lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study

Hertzel C. Gerstein, J.‐F. Yale, Stewart B. Harris et al. · Diabetic Medicine · 2006 · 195 citations

Effect of acarbose on insulin sensitivity in elderly patients with diabetes.

Graydon S. Meneilly, E. A. Ryan, J. Radziuk et al. · Diabetes Care · 2000 · 136 citations · Full text